Brief: Lineage Cell Therapeutics Completes Patient Enrollment In Phase 1/2A Clinical Study Of OpRegen Cell Therapy
11/11/2020 13:17
Nov 11 (Reuters) - Lineage Cell Therapeutics Inc LCTX.A :
* LINEAGE CELL THERAPEUTICS COMPLETES PATIENT ENROLLMENT IN
PHASE
1/2A CLINICAL STUDY OF OPREGEN® CELL THERAPY FOR THE TREATMENT
OF DRY AGE-RELATED MACULAR DEGENERATION
Source text for Eikon: ID:nBwbyntxLa
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million